Xitlali M Magaña

Todos los comentarios aquí emitidos son a título personal.

[Xitlali M Magaña @XitM1]

https://t.co/NtvJNJZOcs

[AJMC @AJMC_Journal]

#ARACOG trial data highlight cognitive effects of androgen receptor pathway inhibitors in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, Dr Alicia Morgans of @DanaFarber told #AJMC ahead of #ASCO26.

Watch here: https://t.co/qxqQ79EqzV

[UroToday.com @urotoday]

Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology. Presented by @CaPsurvivorship @DanaFarber. #ASCO26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/Cldi0bagxp @ALLIANCE_org @ASCO

[Mirrors of Medicine @mirrorsmed]

Invitation by @DrRanaMcKay to join the 30-minute webinar on the new ARASEC & ARACOG clinical trial results.

📅 Wednesday, 10 June at 16:00 CEST / 10:00 AM EDT & on demand thereafter
➡️ Free registration: https://t.co/ylAE2QUNb5

🎙️ With Dr. Alicia Morgans @CaPsurvivorship
📌 Including a case-based discussion
❓️ Take the opportunity to ask your questions

@OncoAlert

[DAVA Oncology @DAVAOnc]

Dr. Charles Ryan @MSKCC outlined ongoing studies with darolutamide across settings. Trials continue to refine its role: DASL/HiCaP with RT, Decipher-guided RT, ARASEC in U.S. mHSPC, sRT ± ADT in BCR & ARACOG evaluating cognitive effects vs enza. PEACE-6 is enrolling. #DAVAGU

[Targeted Oncology @TargetedOnc]

ARASEC: Darolutamide + ADT reduced risk of death by 50% in mHSPC, even with higher rate of ADT control arm receiving subsequent life-prolonging therapy, said @DrRanaMcKay @UCSanDiego #AUA26 https://t.co/np4j2qWNC8

[Zach Klaassen @zklaassen_md]

ARASEC: Daro + ADT in mHSPC – 🇺🇸 prospective, open-label, ph 2 study w/ an external (CHAARTED) control #AUA26 @urotoday @DrRanaMcKay

n=160/arm after PSM
Daro + ADT vs ADT:
📌 PFS: HR 0.29, 95%CI 0.20-0.40
📌OS: HR 0.50, 95%CI 0.30-0.82
📌TT mCRPC: HR 0.26, 95%CI 0.18-0.38
📌rPFS: HR 0.30, 95%CI 0.19-0.48
📌PSA <0.2 ng/mL RR: more than 2x
📌Similar findings for 2 sensitivity analyses:
- ARASEC Daro + ADT arm vs ARANOTE ADT arm
- ARASEC Daro + ADT arm (all pts) vs CHAARTED ADT arm (all pts)

[UroToday.com @urotoday]

Systematic review evaluates radiologic progression-free survival as a surrogate for overall survival in #mHSPC. Neal Shore, MD, FACS @CURCMB & @CaPsurvivorship @DanaFarber highlight practical clinical applications, with both experts noting that patients typically ask how long they will remain on treatment rather than specific survival predictions. #WatchNow on UroToday > https://t.co/7BzGUXaHtF @TheSTARTCenter #ARANOTE

[European Urology @EUplatinum]

💡 Word of Wisdom - ARANOTE trial

The ARANOTE trial reinforces the role of darolutamide + ADT as a well-tolerated, chemotherapy-free intensification strategy for metastatic hormone-sensitive prostate cancer.

🔹 Significant improvement in rPFS (HR 0.54, p < 0.0001)

🔹 Lower fatigue and favorable safety profile

🔹 Supports a patient-centered treatment approach

📖 European Urology 2025; 88:414–420

👉 https://t.co/p3nCdtKE4I

[Santiago Pérez C @STEinforma]

#Entérate “Urge vencer los miedos para ganarle la batalla al cáncer de próstata en México”: Carlos Villagrán “Quico” https://t.co/Vbl91mIVfA

• El cáncer de #próstata continúa siendo la primera causa de muerte por cáncer en población masculina en México, con más de 7 mil muertes

[Bayer México @BayerenMexico]

Carlos Villagrán “Quico”, llama a vencer el miedo y ganarle la batalla al cáncer de próstata

Con un pronóstico de curación de hasta 90% en etapas iniciales, el cáncer de próstata ocupa el primer lugar en muertes en hombres, ya que son diagnosticados en etapas avanzadas, cuando el pronóstico de vida se reduce sensiblemente.

🔗: https://t.co/0pcGV0B2uB

[OPUS INCan @OpusIncanMX]

🔵 DÍA MUNDIAL DEL CÁNCER DE PRÓSTATA 🔵

👨‍⚕️ Si eres hombre y tienes más de 40 años, acude a realizarte una prueba rápida de antígeno prostático totalmente GRATUITA.

📍San Fernando No. 22 (frente a los cajeros)
🕘 9:00 a 12:00
📅 Miércoles 11 de junio
🔖 Cupo limitado

[Oncology Learning Network @OncLearnNetwork]

Based on results from the #ARANOTE trial, the @US_FDA has approved #darolutamide for patients with metastatic castration-sensitive prostate cancer. Learn more: https://t.co/ou7KDu2DpR

#medtwitter #onctwitter

[UroToday.com @urotoday]

🚨 @FDA approves #Darolutamide
Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬

Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA
#ReadNow details on UroToday > https://t.co/1xw7kvZ8YZ @BayerPharma

[Ocurrencias Dr Reyner 🥖 @Dr_Reyner_Solis]

Despiden a residente de qx cardiotorax y le inventan calificaciones reprobatorias.

[UroToday.com @urotoday]

#ARANOTE study shows benefits of deep PSA response with darolutamide. Neal Shore, MD, MSc @CURCMB and @zklaassen_md @GACancerCenter discuss how ultra-low PSA (<0.02 ng/mL) from the ARANOTE trial is changing his practice. Patients hitting this threshold on darolutamide + ADT had markedly better outcomes. #WatchNow > https://t.co/SF1SGzBP6f

[Xitlali M Magaña @XitM1]

@OpusIncanMX Bravo, gran presentación 👏👏👏

[Toni Choueiri, MD @DrChoueiri]

And NOW, TOP 5 PROSTATE CANCER trials of 2024!

1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile.
⛹🏼‍♂️A new player for doublets in mHSPC!

#ESMO24 Dr. Fred Saad @Silke_Gillessen @neerajaiims @umangtalking @DrRanaMcKay @JCO_ASCO

https://t.co/pdSS2DZJcX

[Xitlali M Magaña @XitM1]

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial | Journal of Clinical Oncology https://t.co/CHZI1aswDC

[ScienceLink @sciencelinkonco]

#ESMO24 #ScienceLink #Darolutamida
https://t.co/mxLnaF0rI4

[ScienceLink @sciencelinkonco]

#ESMO24 #ScienceLink #Enzalutamida #Radio223
https://t.co/ijv7nY6KGc